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 26 
Abstract 27 
Morbilliviruses infect a broad range of mammalian hosts including ruminants, carnivores 28 
and humans. The recent eradication of rinderpest virus (RPV), as well as active campaigns 29 
for the human-specific measles virus (MeV), have raised significant concerns that the 30 
remaining morbilliviruses may emerge in so-called vacated ecological niches. Seeking to 31 
assess the zoonotic-potential of non-human morbilliviruses within human populations we 32 
identified that peste des petits ruminants virus (PPRV) - the small ruminant morbillivirus - is 33 
restricted at the point of entry into human cells due to deficient interactions with human 34 
SLAMF1 – the immune cell receptor for morbilliviruses. Using a structure-guided approach, 35 
we characterised a single amino acid change, mapping to the receptor-binding domain in 36 
the PPRV Haemagglutinin (H) protein, which overcomes this restriction. The same mutation 37 
allowed escape from some cross-protective, human-patient, anti-MeV antibodies, raising 38 
concerns that PPRV is a pathogen with zoonotic potential. Analysis of natural variation 39 
within human and ovine SLAMF1 also identified polymorphisms that could correlate with 40 
disease resistance. Finally, the mechanistic nature of the PPRV restriction was also 41 
investigated, identifying charge incompatibility and steric hindrance between PPRV H and 42 
human SLAMF1 proteins. Importantly, this research was performed entirely using surrogate 43 
virus entry assays, negating the requirement for in situ derivation of a human-tropic PPRV 44 
and illustrating alternative strategies for identifying gain-of-function mutations in viral 45 
pathogens. 46 
Importance 47 
A significant proportion of viral pandemics occur following zoonotic transmission events, 48 
where animal-associated viruses jump species into human populations. In order to forewarn 49 
against the emergence of these viruses it is necessary to develop a better understanding of 50 
what determines virus host-range, often at the genetic and structural level. In this research 51 
paper, we demonstrate that the small ruminant morbillivirus, a close relative of measles, is 52 
unable to use human receptors to enter cells; however, a change of a single amino acid in 53 
the virus is sufficient to overcome this restriction. This information will be important for 54 
monitoring this virus’s evolution in the field. Of note, this study was undertaken in vitro, 55 
without generation of a fully infectious virus with this phenotype.  56 
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 57 
Introduction 58 
Morbilliviruses remain significant causes of animal and human disease in populations that 59 
are fundamental to our continued medical, economic and ecological security. Measles virus 60 
(MeV) kills nearly 100,000 people each year despite the availability of efficacious vaccines 61 
(1), while canine distemper virus (CDV) has caused outbreaks in endangered lion, tiger and 62 
primate populations (2, 3). Globally, over 1 billion sheep and goats, approximately 80% of 63 
the world’s small ruminants, are at risk from peste des petits ruminants virus (PPRV) 64 
infection (4). In addition, aquatic mammals such as whales, dolphins, porpoises and seals 65 
are also target species for morbilliviruses; recent epidemics of phocine distemper virus 66 
(PDV) and cetacean morbillivirus (CeMV) in NW Europe have resulted in large fluctuations 67 
in herd immunity in these wildlife populations (5).  68 
In the developing world, PPRV is one of the key challenges to sustainable small ruminant 69 
agriculture (6) where high mortality epidemics, combined with longer-term endemicity, 70 
combine to undermine subsistence farming (7, 8). The distribution of this virus is also 71 
widening with recent outbreaks in Morocco, Georgia, Mongolia and Bulgaria. Collectively, 72 
the economic losses associated with PPRV are now estimated to be $1.45-$2.1 billion 73 
(USD) per year (9, 10). Given these factors and the genetic similarity of morbilliviruses and 74 
their life-cycles, examining the zoonotic potential of non-human morbilliviruses is both 75 
timely and warranted.  76 
A critical feature of morbilliviruses is that they use the same proteinaceous receptors to 77 
enter host cells; Signalling lymphocytic activation molecule F1 (SLAMF1) on immune cells 78 
and Nectin-4 on polarised epithelial cells (11, 12). The current model for morbillivirus 79 
pathogenesis is that SLAMF1 is the key ‘entry receptor’ and that immune cells in the upper 80 
respiratory tract are the first to become infected. These migrate to local lymph nodes, 81 
initiating robust replication and the development of a cell-associated viraemia. At this stage 82 
Nectin-4, which is expressed basolaterally on polarised epithelia in various tissues, serves 83 
as the ‘exit receptor’ facilitating virus escape, i.e. following apical shedding into the lumen of 84 
the lung (12). The universal use of SLAMF1 and Nectin-4 as morbillivirus receptors is long 85 
established (especially for SLAMF1; (13)) and has been the source of intense investigation 86 
with regards to its role in determining host-range (14). This conserved receptor usage is 87 
likely the result of direct evolution from a single common ancestor. Although the host 88 
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tropism of this ancestral virus is unknown, a specific relationship between MeV and 89 
rinderpest virus (RPV) has been identified (Fig.1A) and there is supporting genetic evidence 90 
that MeV emerged in humans following a zoonotic transmission event, perhaps during the 91 
domestication of cattle (15). The currently established morbilliviruses retain a great deal of 92 
genetic similarity [63-66% at the genome level (16)] and have been used interchangeably 93 
during vaccination, since their related antigenicity can, in some contexts, provide effective 94 
cross-protective immunity (17). However, the exact genetic determinants of morbillivirus 95 
host-range remain relatively poorly characterised and it is unclear which stages of the viral 96 
life-cycle contribute to the restricted disease host-range observed in the field or clinic. 97 
Establishing the nature of these barriers is therefore fundamental to the continued control of 98 
these important viruses. For instance, eradication of RPV led to the cessation of vaccination 99 
but as a result there are now realistic fears that PPRV or CDV could spill over into the 100 
global population of 1.5 billion immunologically-naïve cattle (18). 101 
We posited that viral entry may represent one such barrier and may influence the potential 102 
zoonotic transmission of non-human morbilliviruses into human populations. The prevalent 103 
strategy for investigating this restriction would be direct examination of human receptor 104 
usage using field isolates of non-human morbilliviruses, e.g. monitoring PPRV infection of 105 
human SLAMF1-bearing cells. Indeed, this approach was previously employed to 106 
demonstrate that a CDV isolate could not efficiently use human SLAMF1 to enter Vero cells 107 
(19). These authors subsequently demonstrated that repeated passage in the presence of 108 
this receptor could overcome this restriction. In fact, the low-fidelity RNA-dependent RNA-109 
polymerases of RNA viruses have frequently been exploited in this context to identify 110 
genetic mutations that support zoonotic transmission, e.g. influenza H5N1 (20, 21). These 111 
approaches, which normally involve the application of a strong selection pressure through 112 
serial passaging of viruses in vitro or in vivo, are broadly referred to as classical gain-of-113 
function (GOF) experiments and have provided important epidemiological information 114 
together with an improved understanding of pathogen biology. However, the accompanying 115 
in situ creation of GOF viruses has caused controversy, in particular because of bio-safety 116 
concerns regarding the accidental or purposeful release of lab-derived pathogens with 117 
zoonotic potential (22, 23).  118 
In light of these concerns, we hypothesised that by building on our existing structural and 119 
mechanistic understanding of morbillivirus attachment (24), host receptors (12, 25, 26) and 120 
particle entry/fusion (27), we could reliably predict GOF mutants a posteriori, without in situ 121 
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derivation of a GOF morbillivirus. The following research data confirms that these 122 
approaches are valid and further that zoonotic restrictions do exist at the point of non-123 
human morbillivirus entry into human cells, in this case PPRV. As observed in the related 124 
CDV study (19), these restrictions are easily overcome by small amino acid (aa) 125 
substitutions within the receptor binding domain (RBD); however, we were also able to 126 
demonstrate that these mutations have concomitant effects on antibody-mediated 127 
neutralisation. In addition, using our novel approaches and assays we were able to identify 128 
a mechanistic understanding of this restriction at the structural level, all without classical 129 
GOF experiments. 130 
Results 131 
PPRV glycoprotein-mediated fusion is restricted with the human SLAMF1 receptor: 132 
Seeking to address whether receptor usage represents a critical barrier to the zoonotic 133 
transmission of PPRV, we focused on viral interactions with SLAMF1. The H-SLAMF1 134 
protein-protein interaction represents the first-step in virus attachment, prior to activation of 135 
the Fusion (F) protein and virus-cell membrane fusion. Taking advantage of an adapted bi-136 
fluorescence reporter (28), we used a quantitative cell-cell fusion assay to compare 137 
receptor usage by the macromolecular FH complexes of MeV and PPRV. Whilst MeV 138 
induced similar levels of fusion with both human and ovine SLAMF1 (hSLAM and oSLAM, 139 
respectively), PPRV-induced fusion was severely restricted when paired with the non-140 
cognate receptor, hSLAM (Fig.1B). This restriction was subsequently confirmed with H 141 
proteins representing field isolates from all four genetic lineages of PPRV (Fig.1C-F).  142 
Sequence-variation within RBD site 3 may determine virus host-range: The structure 143 
of a chimeric protein representing the complex between MeV H and marmoset SLAM (84% 144 
sequence identity with human SLAM) has been solved (24). Examination of genera-wide 145 
sequence conservation within the four identified interaction motifs (sites 1-4; Fig.2A-B) of 146 
the RBD (24) revealed significant variation (<80% sequence identity) only within site 3 147 
(Fig.2C, supplementary dataset), an interaction between antiparallel intermolecular β-148 
strands of SLAMF1 and H (Fig.2D). A more in depth analysis of intra-species variability 149 
within this site, using representative isolates from all genetic lineages, identified a 150 
contrasting pattern, with conservation of the H sequences 191PTTIR195 and 191R(A/T)VTR195 151 
in various strains of MeV and PPRV, respectively (Fig.2E, supplementary dataset).  152 
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Minor changes to the PPRV H RBD overcome species-specific restrictions: Building 153 
on the hypothesis that variation at site 3 could be an important genetic determinant of host-154 
range, we generated a chimeric PPRV H protein containing the PTTIR sequence at this site 155 
(PPRVMeV H) and examined its capacity to support cell-cell fusion. This mutant had a 156 
significant GOF phenotype with hSLAM (Fig.3A), a change dependent on a single R/P 157 
change at aa position 191 (Fig.3A; R191P). In addition, substitutions within site 3 did not 158 
lead to clear changes in protein stability (Fig.3B), or significantly alter oSLAM-related fusion 159 
(Fig.3C), identifying these mutations as effectively neutral to PPRV infection in sheep, 160 
should they be acquired naturally.  161 
Restriction and GOF phenotypes are recapitulated in a separate model of viral entry. 162 
Using a related entry assay, pseudotyping PPRV FH glycoproteins onto the surface of 163 
replication incompetent HIV-1 particles, we confirmed both the original restriction (Fig.4A) 164 
and the GOF characteristics of the chimeric PPRVMeV H (Fig.4B).  Unlike the primary H-165 
SLAMF1 interaction interface, substitution of residues at the interfaces between adjacent 166 
molecules within the tetrameric H (Form II (24)) had only modest effects upon host-cell 167 
fusion in the presence of either cognate or non-cognate SLAM receptors (data not shown). 168 
When combined this data indicates that small changes within the RBD of PPRV H are 169 
sufficient to alleviate host barriers to zoonotic transmission. Finally, we used a minigenome 170 
assay to confirm that the PPRV RNA replication machinery is functional in human cells, 171 
indicating that entry alone may be the critical barrier to PPRV replication in human cells 172 
(Fig.4C). Although our observations were made using surrogate models of morbillivirus 173 
entry, cell-cell fusion and RNA replication, similar assays have been shown to faithfully 174 
recapitulate native viral activity (28-30). 175 
Random mutagenesis of PPRV H R191 identifies numerous GOF mutations: Our in 176 
vitro receptor usage assays permit rapid screening of H variants for GOF phenotypes 177 
without the need for recombinant virus handling under high-containment. To expand our 178 
analysis of PPRV GOF mutations we used degenerate primers to generate additional R191 179 
mutants, all of which (except R191K, R191E and R191D) were able to significantly 180 
overcome the PPRV hSLAM restriction in cell-cell fusion whilst having a negligible impact 181 
on oSLAM-mediated fusion (Fig.5A). Similar results were observed with a subset of these 182 
mutants adapted for the pseudotype viral entry assay (Fig.5B). In addition the relative 183 
stability of these proteins was again apparently unaffected by mutation at position 191 184 
(Fig.5C). A model of PPRV H in complex with maSLAM shows residue 191 to be in close 185 
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proximity to a hydrophobic region of the SLAMF1 surface (Fig.5D) centred on conserved 186 
residue F131 (Fig.5E). Our analysis suggests that the PPRV hSLAM restriction is caused 187 
by a combination of charge and steric hindrance between PPRV H R191 and this region, 188 
thus providing mechanistic basis for this restriction. It is likely oSLAM has a distinct 189 
conformation in this region that accommodates PPRV H binding as oSLAM lacks the 190 
disulfide bond linking the A and G strands, present in hSLAM (C32-C132, Fig.5E), and has 191 
an extra residue in the A strand compared to hSLAM (supplemental dataset). 192 
Minor variation in mammalian SLAMF1 proteins determines morbillivirus host-range: 193 
To examine the host-specific restrictions to PPRV entry, targeted mutagenesis of hSLAM 194 
was performed by substituting oSLAM residues within the four motifs constituting the H-195 
binding site (HBS) in SLAMF1 (Fig.6A). Generation of an hSLAMoSLAM chimera in this 196 
context was sufficient to partially overcome the PPRV-hSLAM restriction, confirming the 197 
importance of these four motifs in general, and the single L119F substitution in particular, to 198 
virus attachment (Fig.6B). Antibody mediated recognition of this protein; however, appeared 199 
to be modified (Fig.6C), possibly due to modification of the epitope – a finding supported by 200 
flow cytometry performed with a separate commercial antibody (mouse anti-human CD150, 201 
clone A12, BD Biosciences; data not shown). In conclusion, the PPRV-hSLAM restriction 202 
barrier is dependent on the compatibility of several key interacting side-chains within the 203 
HBS of hSLAM and oSLAM. 204 
Host-encoded variability in SLAMF1 effects receptor usage by morbilliviruses: Since 205 
the role of host genetic-variability in morbillivirus entry has not been fully characterised (11), 206 
especially nonsynonymous single nucleotide polymorphisms (nsSNPs) within SLAMF1, we 207 
generated variant SLAMF1 sequences for oSLAM and hSLAM, based on those known in 208 
sheep and human populations (31, 32), and examined their capacity to support PPRV- and 209 
MeV-induced fusion (Fig.7 and Fig.8). Ovine SLAMF1 polymorphisms mapped outside of 210 
the HBS (Fig.7A-B; supplemental dataset) and therefore, unsurprisingly, did not affect 211 
PPRV-induced fusion, even when expressed in their biologically relevant context (haplotype 212 
variants 1-8) (Fig.7C). There was however, no marked difference in protein stability 213 
between the variants (Fig.7D). Due to the abundance (n=104) of nsSNPs recorded for 214 
human SLAMF1 in the Exome Aggregation Consortium (ExAC) database (32), we only 215 
targeted nsSNPs mapping to the HBS (R90H, Q129H, R130H) (Fig.8A-B). All substitutions 216 
significantly reduced MeV-induced fusion (Fig.8C), thus identifying naturally occurring, and 217 
potentially resistance-associated, polymorphisms. R90 sits within a multi-residue charge 218 
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interaction network; the intermediary phenotype of the R90H substitution is likely due to 219 
removal of a salt bridge with D507, reducing the strength of these interactions yet retaining 220 
charge compatibility. As noted by Hashiguchi et al (24), MeV H residue R130 forms a salt 221 
bridge with MeV H residue E75 and plays a significant role in the H-SLAMF1 interaction, 222 
forming the centrepiece of a large interaction network. The complete loss in fusion 223 
conferred by the R130H substitution likely arises from removal of the salt bridge and 224 
disruption of this supporting network. In contrast, the marginal phenotype observed for the 225 
Q129H substitution likely arises from the predominately backbone-mediated nature of the 226 
interaction between β-sheets at site 3 with the Q129 sidechain being on the opposite side of 227 
the β-sheet from the primary interaction site (Fig.2D). In contrast to the oSLAM variants, 228 
hSLAM SNPs within the RBD were detected in variable quantities following Western blot 229 
experiments (Fig.8D), consistent with our previous findings that the antibody epitope may 230 
be modified. Nevertheless, we believe these specific changes may correlate with genetic 231 
polymorphisms that may confer resistance to disease.  232 
Cross-protective neutralisation is effected by gain-of-function mutations within the 233 
PPRV H RBD: We next examined immune-recognition of the isolated GOF mutants by the 234 
host. Morbillivirus infection or vaccination is known to elicit a strong neutralising antibody 235 
(nAb) response to F and/or H, which is critical to life-long immunity in vaccinated or 236 
convalescent hosts (33). The mono-serotypic nature of morbilliviruses and their close 237 
genetic relationship also favours the development of cross-protective nAbs (34), which we 238 
theorised may protect against zoonotic transfer. Using a surrogate virus neutralisation test 239 
(VNT), based on pseudotyped, luciferase-expressing VSVΔG (35), we investigated the 240 
altered antigenicity of our GOF H mutants. Applying a panel of PPRV- (Fig.9A) or MeV-241 
specific (Fig.9B) goat and human sera, respectively, we showed a more variable 242 
neutralisation response in human sera (Fig.9B). In particular, certain human sera failed to 243 
equivalently cross-neutralise the GOF R191P pseudotypes (Fig.9C), indicating that: a) the 244 
RBD represents an important cross-protective epitope, in line with existing knowledge about 245 
nAb epitopes within the MeV RBD (36, 37), and b) in certain sera cross-protection may be 246 
reliant on a limited pool of antibodies targeting only this epitope.  247 
 248 
Discussion 249 
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Morbilliviruses are generally considered to have high host-specificity with disease 250 
manifestations being restricted to a narrow range of hosts, e.g. MeV in humans. 251 
Nevertheless, there is clear evidence that these viruses have jumped species into new 252 
hosts in the past [summarised in Nambulli et al (38)]. Indeed, recent CDV outbreaks in 253 
cynomolgus monkeys in China (39) and Japan (40) continue to illustrate the zoonotic 254 
potential of these viruses. The ability of morbilliviruses to use non-cognate receptors 255 
functionally underpins this ‘zoonotic potential’. This is especially true for SLAMF1 – the 256 
primary entry receptor – since its use is considered vital for establishing infection in the host 257 
(12). Supporting this, Sakai et al., demonstrated that a CDV isolate taken from a moribund 258 
monkey (CYN07-dV) was able to efficiently use utilize marmoset SLAM to enter cells (41). 259 
Further investigations identified that although CYN07-dV could not efficiently use hSLAM, 260 
repeated passage of this virus in Vero-hSLAM cells was sufficient to select GOF mutants, 261 
with a single mutation P541S in CDV H (corresponding to residue P545 in the RBD of MeV 262 
H) being demonstrably important (41). Similar to residue 191, identified herein as important 263 
in determining virus host-range, this residue also appears to vary between morbilliviruses in 264 
a species-specific manner (Fig.2A). Further evidence for the importance of these critical 265 
residues is provided by sequence analysis of RPV viruses adapted to rabbits – wherein a 266 
P191S mutation is observed (Fig.2A). In addition, related aa changes, lying in close 267 
proximity to the CDV H RBD (position 549, corresponding to 553 in MeV, Fig.2A), have also 268 
been implicated in adaptation to varied carnivore hosts (42) and in a study, separate to 269 
those described above, hSLAM (D540G in CDV, corresponding to residue 544 in MeV, 270 
Fig.2A) (19). A key feature of these amino acids is that they lie in, or in close proximity to, 271 
the RBD of H. MeV residues equivalent to CDV P541 and D540 lie at the edge of the region 272 
of hydrophobic interactions between H and SLAMF1 termed ‘site 4’ by Hashiguchi et al. 273 
(24). The role of β-propellers 4 and 5 (in which site 4 sits) of the H head domain in SLAM-274 
binding predates the structural study by Hashiguchi and there is considerable published 275 
mutagenesis data to support their importance in receptor interactions and host-range (14). 276 
However, the structure of the MeV H-SLAM complex illustrated the key importance of 277 
additional residues in β-propeller 6 that make up the complete RBD, in particular P191–278 
R195 in MeV H. This is essential to the formation of site 3 (Fig.2) – an intermolecular β-279 
sheet assembled by the polypeptide backbones of H 191-195 and SLAM 127–131. This 280 
region was not probed in earlier mutagenesis studies (14); however, we have now shown 281 
that amino acid changes in this region play a role in determining host-range. Significantly, a 282 
recent study using a SLAM-blind, recombinant CDV mutant showed that partial reversion in 283 
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a ferret model of disease was associated with compensatory mutations in the RBD, 284 
including the mutation T192A within site 3 (43). Using our functional assays of particle entry 285 
and cell-cell fusion it is difficult to assess the exact biochemical nature of the altered 286 
interactions between H and SLAMF1. The most likely explanation is an alteration to protein-287 
binding affinity; however, more subtle effects on the ability of H to trigger F-mediated fusion 288 
(its fusion-helper function) or the relative stability of H dimers and tetramers is also 289 
possible, especially given the close proximity of position 191 to the H-stalk. Whilst we did 290 
assess the relative stability of the mutants (Fig.3B and Fig.5C) these questions are best 291 
answered using direct protein-binding assays, the subject of ongoing investigations in our 292 
laboratory. 293 
Separately, we demonstrated that changes within the HBS on SLAM can also have 294 
significant functional consequences on viral glycoprotein activity (Fig.6-8). Using 295 
sequencing and structural modelling of non-human SLAMF1s Ohishi et al identified a 296 
number of H residues (63, 66, 68, 72, 84, 119, 121, and 130) as being potentially important 297 
in determining host-range (44). A number of these residues (63, 72, 119 and 130) were 298 
subsequently shown to lie directly within the SLAMF1 HBS (24) confirming their likely 299 
importance. These conclusions are now supported by our findings that modifications to 300 
these residues in hSLAM, in particular L119 and R130, altered the host-specificity of H 301 
interactions (Fig.6 and Fig.8, respectively).  302 
Given the universal usage of SLAMF1 as an entry receptor for morbilliviruses and the 303 
relative similarity of both the RBD of H and the HBS of SLAMF1 (Fig.2A and 6A) at this 304 
interface it is perhaps not surprising that specific amino acids appear critical in determining 305 
virus host-range. The recent observation that the morbillivirus RBD (which overlaps for both 306 
SLAMF1 and Nectin-4 binding) is also a dominant and conserved neutralising antibody 307 
epitope has helped to explain both the monoserotypic nature of morbilliviruses and the 308 
success of live attenuated vaccines (37). Our observation that changes to the RBD also 309 
affected antibody-mediated neutralisation (Fig.9) supports this conclusion and further 310 
indicates that, to some degree, this region may also represent an essential epitope for 311 
cross-protective neutralising antibody binding. 312 
The proposition that receptor tropism can inform studies on the zoonotic potential of 313 
paramyxoviruses is an emerging area of interest (45, 46). As discussed by Zeltina et al., 314 
(46) the morbilliviruses and henipaviruses are especially interesting in this context because 315 
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they bind proteinaceous receptors (SLAMF1 and Nectin-4 or EphrinB2/3, respectively) – 316 
with viral affinity for these proteins potentially determining host-range. In drawing 317 
conclusions on morbillivirus host-range, these authors relied on analysis of the overall 318 
variation of the RBD; however, by focusing separately on the four motifs that constitute this 319 
domain, we were able to identify a single site relevant to host-range, a hypothesis that was 320 
confirmed in our functional study and through analysis of nsSNPs within human SLAMF1. 321 
Our approach highlights the need for in-depth analysis of the structural interface between 322 
attachment protein and receptor, and indicates morbillivirus host-range may be determined 323 
by only a small number of amino acids within the entirety of the RBD. Whether this applies 324 
to more distantly related viruses, such as feline morbillivirus (Fig.1A) or the recently 325 
identified morbilliviruses of bats and rodents (47), remains to be determined.  326 
While there is no clear indication that enhanced entry alone is sufficient to confer a 327 
pathogenic phenotype to PPRV in humans, our minigenome experiments indicate that the 328 
production of nascent particles in virus-infected human cells is likely. However, acquisition 329 
of a novel receptor-usage phenotype might not immediately relate to pathogenesis in the 330 
host. Tellingly, the in-host reversion of receptor usage by a SLAM-blind CDV in ferrets did 331 
not restore virulence in vivo, even in a permissive host (43), perhaps because of only a 332 
partial reversion in SLAM-binding. Separately, transgenic mice expressing hSLAM do not 333 
fully reconstitute a natural MeV infection when challenged (48).  Other factors, beyond 334 
entry, are also likely to be important in the development of pathogenic and/or transmission 335 
phenotypes, e.g. the efficiency of innate immune antagonism by the viral accessory 336 
proteins C and V, which are known to antagonise the host’s interferon response and may 337 
be species specific in their mechanism of action (49). However, since adaptation to a new 338 
host (through mutation and selection mechanisms) requires genomic replication inside 339 
infected cells, we would maintain that entry is the most important barrier to overcome, at 340 
least initially. This highlights the importance of both receptor usage and cross-protective 341 
antibodies in morbillivirus zoonotic transmission events, conclusions summarised in a 342 
general model of morbillivirus emergence (Fig.10A). Here the probability of a major 343 
outbreak in atypical host populations is likely to be dependent on receptor usage 344 
phenotypes, the proportion of the population with cross-protective antibodies, as well as the 345 
basic reproduction number of the emergent virus. Applying this model to PPRV emergence 346 
in humans using a previously established R0 for this virus (Fig.10B) highlights the 347 
requirement for continued vaccination in human populations. This trend is likely to be 348 
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applicable across the spectrum of morbillivirus hosts, particularly in cattle which no longer 349 
have high levels of immunity following the eradication of RPV and the cessation of 350 
vaccination.  351 
Whilst there are examples of single aa changes in H conferring enhanced tropism to human 352 
receptors, e.g. CDV (19), these events were identified using classical GOF experiments. 353 
Our study highlights how it is possible to identify pathogens with zoonotic potential and 354 
GOF variants by structure-guided biochemical investigations. Using these ‘alternative’ GOF 355 
approaches we have demonstrated that receptor usage and cross-protective nAbs are 356 
important and distinct barriers to morbillivirus zoonotic transmission, whose removal could 357 
have serious consequences to the ecological relationship between these viruses and their 358 
hosts; a finding that is especially prescient given the ongoing eradication campaigns for 359 
PPRV and MeV, as well as the recent eradication of RPV. In addition, in light of our findings 360 
with cross-neutralising anti-MeV nAbs, we encourage epidemiological surveillance of 361 
mutations in this region, akin to active programmes for influenza virus (50). The 1986 362 
isolation of a K191-encoding PPRV in the United Arab Emirates (accession number; 363 
KJ867545) highlights the potential for natural variation at this position and supports the 364 
continued vaccination of humans and goats alike to both maintain high herd immunity levels 365 
and prevent emergence of PPRV in human populations.  366 
Materials and Methods 367 
Plasmids and mutagenesis: MeV F and H ORFs were amplified from a patient isolate of 368 
MeV from Dublin, Ireland (51) following RT-PCR on RNA from infected Vero hSLAM cells. 369 
PPRV constructs were amplified from the PPRV reference strain (described previously (16); 370 
AJ849636, Turkey 2000, field isolate, lineage IV). o/h SLAMF1 were isolated from sheep 371 
and human monocytic cells, respectively. All constructs were cloned into pcDNA3.1 372 
(ThermoFisher). MeV H expression constructs were amplified to include an N-terminal HA-373 
tag. Site-directed mutagenesis was confirmed by sequencing. Specific cloning strategies 374 
and primer sequences are available upon request. 375 
Cell-cell fusion assays: HEK293T effector cells were transfected (using Transit-X2 376 
transfection reagent (Mirus), as per the manufacturer’s instructions) with 500 ng each of 377 
MeV or PPRV F and H expression constructs and 250 ng of the 1-7 fragment of rLuc-GFP 378 
(52). Separately, target cells were transfected with 1 μg of varying SLAMF1-expression 379 
constructs, as well as 250 ng of the 8-11 fragment of rLuc-GFP. Forty-eight hours later 380 
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effector and target cells were washed, counted and co-cultured at a ratio of 1:1 in white-381 
walled 96-well plates to a final density of 1x105 cells per well. 16-24 hours later the Renilla 382 
luciferase activity in fused cells was measured (in a Promega GloMax multi-mode plate 383 
reader) by removing the media and adding 2 μg/mL of cell-permeable coelenterazine 400A 384 
(Biotium) in PBS. Apart from Fig.1D-E all fusion assays were performed with a cognate F 385 
protein from the same viral strain. For Fig.1D-E the F protein from the Senegal lineage 1 386 
strain was used with PPRV Senegal, Benin, Kenya and Ethiopia H. PPRV F proteins are 387 
highly conserved with >95% identity between strains (data not shown) Four or more co-388 
culturing biological replicates were performed for each biological condition. All experiments 389 
were performed a minimum of three times. 390 
Pseudotyped viruses: Morbillivirus F and H expression constructs with truncated 391 
cytoplasmic tails, (ΔF/ΔH, 30 and 24 aa, respectively) were cloned and used for 392 
pseudotype production and quantitative entry experiments as described previously (30). 393 
Briefly, for pseudotype production HEK293T cells were plated at a density of 7.5x105 cells 394 
per well in 6-well dishes and the following day transfected with 3.5 µg each of the 395 
pcDNA3.1-ΔF/ΔH constructs, as well as 1.5 µg of p8.91 (encoding for HIV-1 gag-pol) and 1 396 
µg of CSFLW (the luciferase reporter expressing lentivirus-backbone). Matched cognate 397 
combinations of F and H from PPRV and MeV strains were used in all assays. 398 
Supernatants containing pseudotyped viruses were harvested at 72 hours post-transfection, 399 
clarified by centrifugation and frozen to -80°C. Target cells were plated at a density of 2x104 400 
cells per well in 96-well dishes one day prior to transduction/infection for 72 hours. Firefly 401 
luciferase activity in these cells was assayed using the Luciferase Assay System (Promega) 402 
according to the manufacturer’s instructions and a Promega GloMax multimode plate 403 
reader.  404 
 405 
Surrogate VNTs: To prepare VSVΔGluc pseudotypes, HEK293T cells were transfected 406 
with the H and F expression vectors from the respective virus, followed by super-infection 407 
with VSVΔGluc (VSVG) as described (53, 54). Supernatants were harvested 48 hours post-408 
infection, aliquoted and frozen at -80oC. The titre of each viral pseudotype stock was 409 
estimated by preparing serial dilutions in triplicate and plating onto 293 canine SLAM cells 410 
followed by incubation for 48 to 72 hours at 37oC, at which time luciferase substrate was 411 
added (Steadylite plus™, Perkin Elmer) and the signal analysed on a Microbeta 1450 Jet 412 
luminometer (Perkin Elmer). Canine SLAM was used because neither MeV or PPRV 413 
appear restricted with this receptor (data not shown). The viral titre [50% tissue culture 414 
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infectious dose (TCID50)] was calculated using the Spearman-Kärber formula. To measure 415 
virus neutralisation, four-fold serum dilutions ranging from 1:8 to 1:32,768 were prepared in 416 
triplicate and  added to 293 canine SLAM cells in 96-well white flat-bottomed plates, 417 
followed by 2.5x103 TCID50 of VSVΔG(F&H) pseudotype. Plates were incubated for 48 418 
hours at 37oC, at which time luciferase assays were performed.  Antibody titres were 419 
calculated by interpolating the point at which there was a 90% reduction in luciferase 420 
activity (90% neutralisation, inhibitory concentration 90 or EC90). 421 
Minigenome assays: Minigenome assays were performed as described previously (55) 422 
using human A549 cells and a PPRV Turkey 2000 minigenome with a Gaussia luciferase 423 
reporter gene. 424 
Protein biochemistry: All protein samples were prepared in 1X radio-immunoprecipitation 425 
assay (RIPA) buffer containing protease inhibitors (ThermoFisher). Briefly, existing growth 426 
media was removed and cells were washed in phosphate buffered saline (PBS) before 427 
being pelleted by centrifugation. Pelleted cells were then resuspended in 1X RIPA and left 428 
on ice for 10 minutes before repeated centrifugation at high speed (16,000 g) for a further 429 
10 minutes at 4°C. Protein lysate-containing supernatants were then stored at -20°C until 430 
required. Samples for Western blot were analysed by SDS-PAGE, semi-dry, PVDF-based, 431 
transfer and blotting in TBS-Tween containing 5% (w/v) milk powder. All primary antibodies 432 
were incubated overnight at 4°C. Western blots were performed using the following 433 
antibodies: anti-morbillivirus/MeV Haemagglutinin (cytoplasmic tail) (H-cyt; rabbit polyclonal 434 
at 1:1000, gifted from R. Cattaneo (56)), anti-FLAG (1:1000, Cell Signaling (CS), 9A3), anti-435 
GAPDH (1:1000, 14C10, CS), anti-HA (1:1000, CS, C29F4), anti-HIS (1:1000, CS), SLAM 436 
(N-19): Santa Cruz sc-1334, and standard HRP-linked secondary antibodies (CS).  437 
Probability of a major outbreak: Mathematical modelling was used to assess the 438 
probability of a PPRV outbreak in humans. Consider a cross-protected population where a 439 
proportion n of individuals are completely protected by cross-protective nAbs, and the rest 440 
have no protection. The rate of spillover events of a PPRV variant, capable of replication 441 
within humans, into this population can be written as 𝑧(𝑛) = 𝑧(0)(1 − 𝑛), where 𝑧(0) is the 442 
rate of spillover into a fully susceptible population in which no individuals are cross 443 
protected. Once a spillover has occurred, the probably of a major outbreak is given by 444 
𝑝(𝑛) = 1 −
1
(1−𝑛)𝑅0
 if (1 − 𝑛)𝑅0 > 1, or 𝑝(𝑛) = 0 otherwise (57) where 𝑅0 is the basic 445 
reproduction number of the PPRV variant in a fully susceptible population where no 446 
individuals are cross protected (Fig.3H, black line). Multiplying these two quantities gives 447 
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the expected rate of major outbreaks, 𝑚(𝑛) = 𝑧(𝑛)𝑝(𝑛). Since 𝑧(0) is an unknown quantity, 448 
we determined the relative rates of spillover events and major outbreaks in cross-protected 449 
compared to fully susceptible populations, giving 𝑧(𝑛) 𝑧(0)⁄ = (1 − 𝑛) and 450 
𝑚(𝑛) 𝑚(0) =
𝑅0(1−𝑛)−1
𝑅0−1
⁄ , respectively (Fig.3H, blue and red lines). 451 
Bioinformatics and modelling: Comparison of aa sequences was performed using the 452 
Vector Nti package (ThermoFisher), and the AlignX embedded software as well as the 453 
Weblogo online server (58). Information regarding nsSNPs within human SLAMF1 was 454 
obtained from the ExAC database (32), whilst ovine SLAMF1 variation was mapped as 455 
described previously (31). Models of the PPRV H and ovine SLAM structures were 456 
generated using the I-TASSER web server (59) using the MeV H and marmoset SLAM 457 
structures from PDB ID 3ALX (24) as templates, respectively. Models of oSLAMF1:MeV H 458 
or PPRV H:maSLAMF1 complexes were generated by superposing models of oSLAM or 459 
PPRV H onto maSLAM or MeV H, respectively, from the high resolution structure of the 460 
complex (PDB ID: 3ALX) (24). Molecular images were generated using PyMOL 461 
(Schrodinger LLC). 462 
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Figures and Legends: 480 
Figure 1: PPRV glycoprotein-mediated fusion is restricted with the human SLAMF1 481 
receptor. (A) The established mammalian morbilliviruses (phylogenetic tree assembled 482 
from complete genome sequences using Vector Nti, 0.1 scale bar; nt substitutions). (B) 483 
MeV cell-cell fusion is efficient when either hSLAM (black) or oSLAM (grey) is present on 484 
target cells; however, PPRV is restricted to efficient fusion with oSLAM only. Minimal fusion 485 
is seen with HEK293 cells alone (right panel). Raw Renilla luciferase assay data is shown 486 
(RLU). Non-cognate virus-receptor interactions are indicated with patterned shading. (C) 487 
The current distribution of PPRV according to the World Organisation for Animal Health 488 
(OIE) and the Food and Agriculture Organisation for the United Nations (FAO). The 489 
countries highlighted in red have ongoing, or have previously had, outbreaks of PPRV. 490 
Additional representative isolates of PPRV, genetic lineages I-IV, from the indicated 491 
countries: Senegal, Benin, Kenya and Ethiopia, were also used in this study to confirm the 492 
hSLAM restriction. The aa sequences of the PPRV H RBD at site 3 (aa 191-195) from 493 
these additional isolates is shown (RAVTR or RTVTR). (D/E) All PPRV H proteins tested 494 
showed a similar restriction with hSLAM-mediated cell-cell fusion. Results are expressed 495 
relative to cognate virus-host interactions, i.e. MeV-hSLAM or PPRV (Turkey, IV)-oSLAM. 496 
Non-cognate virus-receptor interactions are indicated with patterned shading.  (F) Western 497 
blot analysis of the various PPRV H proteins, from distinct lineages, expressed in the cell-498 
cell fusion assays; both monomeric and dimeric H were detected using an antibody 499 
targeting the cytoplasmic tail of H (H-cyt). Graphs denote the mean activity from >4 500 
biological replicates with error bars denoting standard deviation. Statistical analysis: One 501 
way ANOVA with Dunnett’s multiple comparisons test (p= ns, non-significant, *<0.05, 502 
**<0.01, ***<0.005, ****<0.001). 503 
Figure 2: Sequence-variation within RBD site 3 may determine virus host-range. (A) 504 
Multiple alignments of various morbillivirus H proteins focusing on the 4 sites that constitute 505 
the RBD. The surrounding sequences are shown for clarity, although the exact aa positions 506 
and sequences are indicated (relative to MeV – Dublin). Of note a number of specific aa 507 
residues are found in more than one site (Y524, F552). The PPRV reference sequence 508 
used in this study is PPRV AJ849636. The lapinized RPV strain is AB547190. (B) Structure 509 
of measles virus H (MeV H) in complex with marmoset SLAMF1 (maSLAM) receptor (PDB 510 
3ALX) (24). Top: Complex is shown as ribbons. Bottom: The interaction interfaces between 511 
MeV and maSLAM are shown as molecular surfaces, labelled 1-4 and coloured as defined 512 
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by Hashiguchi et al (24). (C) Multiple alignments of various morbillivirus H proteins focusing 513 
on the 4 sites that constitute the RBD. The surrounding sequences are shown for clarity, 514 
although the exact aa positions and sequences are highlighted. Conservation within the 515 
separate sites was analysed using the WebLogo online server. The overall variation 516 
detected (given as percentage identity) within each site is also indicated. The sequences 517 
used for this analysis are provided in the supplementary dataset together with the relative 518 
aa positions. (D) MeV H:maSLAM interaction region 3 comprises an interaction between 519 
adjacent anti-parallel β-sheets. Ribbon representation is coloured as in (B), with selected 520 
residues shown as sticks (MeV H carbon atoms pink, maSLAM carbon atoms red) and 521 
selected backbone hydrogen bonds shown (yellow dots). (E) Morbillivirus inter-species aa 522 
variability within site 3 (aa 191-195, N-C aa termini indicated) is high, (comparative 523 
sequence alignment; top); however, intra-species variability is markedly lower (bottom; 524 
analysis of a complete spectrum of circulating MeV and PPRV genotypes – see 525 
supplementary dataset).  526 
Figure 3: Minor changes to the PPRV H RBD overcome species-specific restrictions. 527 
(A) A chimeric PPRV H containing the site 3 aa sequence of MeV (RTVTR – PTTIR) is no 528 
longer restricted by hSLAM in the cell-cell fusion assay. Results are expressed relative to 529 
WT PPRV H and hSLAM interactions (see Fig.1B). (B) Western blot analysis of the WT and 530 
mutant PPRV H expressed in effector cells shows equivalent expression of both monomeric 531 
and dimeric H protein. (C) MeV chimeric mutations within PPRV H site 3 have a neutral 532 
effect on oSLAM-dependent fusion. Results are expressed relative to WT PPRV H and 533 
oSLAM interactions. All panels: graphs denote the mean activity from biological replicates 534 
with error bars denoting standard deviation. Statistical analysis: One way ANOVA with 535 
Dunnett’s multiple comparisons tests; p= ns, non-significant *<0.05, **<0.01, ***<0.005, 536 
****<0.001. 537 
Figure 4: Restriction and GOF phenotypes are recapitulated in a separate model of 538 
viral entry. (A) An equivalent PPRV H hSLAM restriction was observed using a PPRV-539 
pseudotyped (PP) HIV-1 based entry assay. Graph denotes the mean activity from >4 540 
biological replicates with error bars denoting standard deviation. Non-cognate virus-541 
receptor interactions are indicated with patterned shading. Statistical analysis: Two-way 542 
ANOVA with Sidak’s multiple comparisons test p= ns, ****<0.001. NE; non-enveloped 543 
control pseudotypes. (B) PPRV PPs bearing PPRVMeV H protein chimeras overcome the 544 
hSLAM restriction, specifically the full site 3 chimera (PTTIR) and the single R191P 545 
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mutation, while having minimal effects on oSLAM mediated fusion. Results are expressed 546 
as percentage change relative to PPRV WT H (unmutated) PP entry. Graphs denote the 547 
mean activity from >4 biological replicates with error bars denoting standard deviation. Non-548 
cognate virus-receptor interactions are indicated with patterned shading. Statistical 549 
analysis: One way ANOVA with Dunnett’s multiple comparisons test; p= ns; non-significant, 550 
*<0.05, **<0.01, ***<0.005, ****<0.001. (C) A PPRV minigenome, supported by trans-551 
expression of PPRV N, P and L proteins, is functional in human A549 cells. Experiments 552 
were performed in triplicate. Error bars denote standard deviation; luciferase assays were 553 
normalized against untransfected cells. 554 
Figure 5: Random mutagenesis of PPRV H R191 identifies numerous GOF mutations. 555 
(A) Using the standard cell-cell fusion assay; random mutagenesis of the Arginine (R) 556 
residue in PPRV H (R191) identified that multiple aa changes are sufficient to overcome the 557 
PPRV-hSLAM restriction (black bars). The affects of these aa changes on oSLAM-558 
dependent fusion are also indicated (grey bars). All results are expressed relative to PPRV 559 
WT H (unmutated) interactions with h/o SLAM, (left/right panel respectively). (B) Similar 560 
results were observed using a subset of these mutants and the PPRV-pseudotyped (PP) 561 
HIV-1 based entry assay; all results are expressed as percentage change relative to PPRV 562 
WT (unmutated) H PP entry. Left panel; hSLAM, right panel; oSLAM.  (C) Varied mutations 563 
at PPRV H aa position 191 do not affect the relative stability of this protein. kDa size 564 
markers refer to SDS-PAGE ladder positions. (D) Model of PPRV H in complex with 565 
maSLAM. The maSLAM surface is coloured by residue hydrophobicity, from white (polar) to 566 
green (hydrophobic). (E) H residue 191 interacts with conserved SLAM residue 131. In the 567 
maSLAM + MeV H complex (top) the prolidyl ring of P191 forms a stacking interaction with 568 
the hydrophobic F131 side chain. The adjacent disulfide bond that connects the A and G 569 
strands (A# and G#) of the maSLAM Ig domain is highlighted. The presence of the bulky 570 
charged residue arginine at this location in PRRV H (bottom) would likely interfere with 571 
complex formation. Residues in MeV H:maSLAM interaction region 3 are coloured as in 572 
Fig.2D. All panels: graphs denote the mean activity from >4 biological replicates with error 573 
bars denoting standard deviation. Statistical analysis: One way ANOVA with Dunnett’s 574 
multiple comparisons test; p= *<0.05, **<0.01, ***<0.005, ****<0.001. 575 
Figure 6: Minor variation in mammalian SLAMF1 proteins determines morbillivirus 576 
host-range. (A) An aa alignment of the HBS of hSLAM and oSLAM highlights variation in 577 
sites 1-4 between the two proteins (*; analysis of site 4 was extended to include S73 and 578 
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N76). (B) Stepwise mutation of the hSLAM sequence to generate a site 3/4 oSLAM chimera 579 
is sufficient to overcome the PPRV-hSLAM restriction. Results are expressed relative to WT 580 
PPRV H protein interactions with the unmutated WT hSLAM receptor. (C) Western blot 581 
analysis of the WT and mutant hSLAM sequences expressed in target cells (antibody: 582 
SLAM [N-19]: Santa Cruz sc-1334). Graphs denote the mean activity from >4 biological 583 
replicates with error bars denoting standard deviation. Statistical analysis: One way ANOVA 584 
with Dunnett’s multiple comparisons test (p= ns, non-significant, *<0.05, **<0.01, ***<0.005, 585 
****<0.001). 586 
Figure 7: Host variation in oSLAM is not associated with altered PPRV-glycoprotein 587 
mediated fusion. (A) Amino acid variants encoded within the ovine SLAMF1 gene locus 588 
were characterised in a diverse set of 171 sheep with available genome sequences. From 589 
these data, a rooted maximum parsimony phylogenetic tree of the haplotype-phased 590 
protein variants was constructed. Each node in the tree represents a different, naturally 591 
occurring, protein isoform that varies by single amino acids. The areas of the circles are 592 
proportional to the variant frequencies (see supplemental dataset). (B) Model of MeV H 593 
(white ribbons) in complex with oSLAM (light blue molecular surface), showing that the 594 
ovine SNPs (pink sticks) lie outside the likely HBS (residues equivalent to maSLAM HBS 595 
are coloured as in Fig 2B). (C) Variation in oSLAM does not markedly effect the cell-cell 596 
fusion potential of PPRV F and H proteins. Results are expressed relative to the dominant 597 
variant of oSLAM (V1; S9R85H91D94C272). (D) Western blot analysis of the eight variant 598 
oSLAMs (V1-V8) expressed in target cells (antibody: HIS-tag). The graph denotes the 599 
mean activity from >4 biological replicates with error bars denoting standard deviation. 600 
Statistical analysis: One way ANOVA with Dunnett’s multiple comparisons test; p= *<0.05, 601 
**<0.01, ***<0.005, ****<0.001. 602 
Figure 8: Minor frequency nsSNPs within the hSLAM HBS are associated with altered 603 
MeV-glycoprotein mediated fusion. (A) Allele frequencies of human SLAMF1 nsSNPs 604 
within the HBS of hSLAM. (B) Residues equivalent to nsSNPs found within the publicly 605 
available EXAC database and the hSLAM HBS are shown on the molecular surface of 606 
maSLAM (HBS regions coloured as in Fig.2B). (C) Variation within the hSLAM HBS 607 
reduced MeV-induced cell-cell fusion. Results are expressed relative to the WT hSLAM aa 608 
sequence (Uniprot access: Q13291).  (D) Western blot analysis of the three variant 609 
hSLAMs (and dominant sequence, WT) expressed in target cells. The graph denotes the 610 
mean activity from >4 biological replicates with error bars denoting standard deviation. 611 
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Statistical analysis: One way ANOVA with Dunnett’s multiple comparisons test; p= *<0.05, 612 
**<0.01, ***<0.005, ****<0.001. 613 
Figure 9: Cross-protective neutralisation is effected by gain-of-function mutations 614 
within the PPRV H RBD. (A) Neutralisation of WT and R191P-bearing PPRV PPs by sera 615 
from goats (PPRV-specific; left panel; n=10) and (B) humans (MeV-specific, right panel; 616 
n=8). EC90 titres (colour-matched by serum) are shown; error bars denote standard error of 617 
the mean. Antibody titres were calculated by interpolating the point at which there was a 618 
90% reduction in luciferase activity (90% neutralisation, inhibitory concentration 90 or EC90). 619 
Statistical analysis was performed using the non-parametric Wilcoxon matched-pairs signed 620 
rank test (*; p=<0.05). (C) In certain human serum, e.g. 377 and 584 (red and green 621 
squares, respectively) R191P confers a nAb escape phenotype to PPRV PPs.  Surrogate 622 
VNT titrations were performed with individual MeV-specific human sera to calculate cross-623 
protective titres against WT and R191P PPRV pseudotypes. Titrations were performed in 624 
triplicate on non-restricted HEK293 canine SLAM cells with error bars denoting standard 625 
error of the mean. The colouring of the lines within the graphs matches the sera used in the 626 
summary EC90 panel (B). 627 
Figure 10: PPRV has zoonotic potential in human populations. (A) Factors influencing 628 
the emergence of morbilliviruses in atypical hosts. (B) The chance of PPRV emergence in 629 
humans. Blue: the rate of spillovers of a variant of PPRV, capable of human-to-human 630 
transmission, into a human population in which a fraction n of individuals have cross-631 
protective nAbs, relative to the equivalent rate in a population where no individuals have 632 
cross-protective nAbs [𝑧(𝑛) 𝑧(0)⁄ ]. Black: Following a single spillover event, the probability of 633 
a major outbreak driven by human-to-human transmission [𝑝(𝑛)]. Red: The relative rate of 634 
major outbreaks in humans, compared to a population where no individuals have cross-635 
protective nAbs [𝑚(𝑛) 𝑚(0)⁄ ]. We assume that a variant of PPRV capable of human-to-636 
human transmission, has an R0 = 6.85 in human populations with no cross-protective nAbs. 637 
This is the estimated basic reproduction number of PPRV in Afghan (Bulkhi) sheep in 638 
Pakistan (60). 639 
 640 
References 641 
1. WHO. 2015. Measles Fact Sheet 286. 642 
 o
n
 Septem
ber 24, 2018 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
21 
 
2. Ohishi K, Suzuki R, Maeda T, Tsuda M, Abe E, Yoshida T, Endo Y, Okamura M, 643 
Nagamine T, Yamamoto H, Ueda M, Maruyama T. 2014. Recent host range 644 
expansion of canine distemper virus and variation in its receptor, the signaling 645 
lymphocyte activation molecule, in carnivores. J Wildl Dis 50:596-606. 646 
3. Terio KA, Craft ME. 2013. Canine distemper virus (CDV) in another big cat: should 647 
CDV be renamed carnivore distemper virus? MBio 4:e00702-13. 648 
4. OIE, FAO. 2015. Global control and eradication of peste des petits ruminants. PPRV 649 
summary document. 650 
5. Bodewes R, Morick D, van de Bildt MW, Osinga N, Rubio Garcia A, Sanchez 651 
Contreras GJ, Smits SL, Reperant LA, Kuiken T, Osterhaus AD. 2013. Prevalence of 652 
phocine distemper virus specific antibodies: bracing for the next seal epizootic in 653 
north-western Europe. Emerg Microbes Infect 2:e3. 654 
6. Banyard AC, Parida S, Batten C, Oura C, Kwiatek O, Libeau G. 2010. Global 655 
distribution of peste des petits ruminants virus and prospects for improved diagnosis 656 
and control. J Gen Virol 91:2885-97. 657 
7. Albina E, Kwiatek O, Minet C, Lancelot R, Servan de Almeida R, Libeau G. 2013. 658 
Peste des Petits Ruminants, the next eradicated animal disease? Vet Microbiol 659 
165:38-44. 660 
8. Kumar N, Maherchandani S, Kashyap SK, Singh SV, Sharma S, Chaubey KK, Ly H. 661 
2014. Peste des petits ruminants virus infection of small ruminants: a comprehensive 662 
review. Viruses 6:2287-327. 663 
9. OIE, FAO. 2015. Global Strategy for the Control and Eradication of PPR.  World 664 
Organisation for Animal Health (OIE); Food and Agriculture Organization of the 665 
United Nations (FAO), http://www.fao.org/3/a-i4460e.pdf. 666 
10. Jones BA, Rich KM, Mariner JC, Anderson J, Jeggo M, Thevasagayam S, Cai Y, 667 
Peters AR, Roeder P. 2016. The Economic Impact of Eradicating Peste des Petits 668 
Ruminants: A Benefit-Cost Analysis. PLoS One 11:e0149982. 669 
11. Birch J, Juleff N, Heaton MP, Kalbfleisch T, Kijas J, Bailey D. 2013. Characterization 670 
of ovine Nectin-4, a novel peste des petits ruminants virus receptor. J Virol 87:4756-671 
61. 672 
12. Muhlebach MD, Mateo M, Sinn PL, Prufer S, Uhlig KM, Leonard VH, Navaratnarajah 673 
CK, Frenzke M, Wong XX, Sawatsky B, Ramachandran S, McCray PB, Jr., Cichutek 674 
K, von Messling V, Lopez M, Cattaneo R. 2011. Adherens junction protein nectin-4 is 675 
the epithelial receptor for measles virus. Nature 480:530-3. 676 
13. Tatsuo H, Ono N, Yanagi Y. 2001. Morbilliviruses use signaling lymphocyte 677 
activation molecules (CD150) as cellular receptors. J Virol 75:5842-50. 678 
14. Vongpunsawad S, Oezgun N, Braun W, Cattaneo R. 2004. Selectively receptor-blind 679 
measles viruses: Identification of residues necessary for SLAM- or CD46-induced 680 
fusion and their localization on a new hemagglutinin structural model. J Virol 78:302-681 
13. 682 
15. Pearce-Duvet JM. 2006. The origin of human pathogens: evaluating the role of 683 
agriculture and domestic animals in the evolution of human disease. Biol Rev Camb 684 
Philos Soc 81:369-82. 685 
16. Bailey D, Banyard A, Dash P, Ozkul A, Barrett T. 2005. Full genome sequence of 686 
peste des petits ruminants virus, a member of the Morbillivirus genus. Virus research 687 
110:119-124. 688 
17. Mariner JC, House JA, Mebus CA, van den Ende MC. 1993. The use of 689 
thermostable Vero cell-adapted rinderpest vaccine as a heterologous vaccine 690 
against peste des petits ruminants. Res Vet Sci 54:212-6. 691 
 o
n
 Septem
ber 24, 2018 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
22 
 
18. Fournie G, Jones BA, Beauvais W, Lubroth J, Njeumi F, Cameron A, Pfeiffer DU. 692 
2014. The risk of rinderpest re-introduction in post-eradication era. Prev Vet Med 693 
113:175-84. 694 
19. Bieringer M, Han JW, Kendl S, Khosravi M, Plattet P, Schneider-Schaulies J. 2013. 695 
Experimental adaptation of wild-type canine distemper virus (CDV) to the human 696 
entry receptor CD150. PLoS One 8:e57488. 697 
20. Herfst S, Schrauwen EJ, Linster M, Chutinimitkul S, de Wit E, Munster VJ, Sorrell 698 
EM, Bestebroer TM, Burke DF, Smith DJ, Rimmelzwaan GF, Osterhaus AD, 699 
Fouchier RA. 2012. Airborne transmission of influenza A/H5N1 virus between ferrets. 700 
Science 336:1534-41. 701 
21. Imai M, Watanabe T, Hatta M, Das SC, Ozawa M, Shinya K, Zhong G, Hanson A, 702 
Katsura H, Watanabe S, Li C, Kawakami E, Yamada S, Kiso M, Suzuki Y, Maher EA, 703 
Neumann G, Kawaoka Y. 2012. Experimental adaptation of an influenza H5 HA 704 
confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in 705 
ferrets. Nature 486:420-8. 706 
22. Imperiale MJ, Casadevall A. 2016. Zika Virus Focuses the Gain-of-Function Debate. 707 
mSphere 1. 708 
23. Lipsitch M, Galvani AP. 2014. Ethical alternatives to experiments with novel potential 709 
pandemic pathogens. PLoS Med 11:e1001646. 710 
24. Hashiguchi T, Ose T, Kubota M, Maita N, Kamishikiryo J, Maenaka K, Yanagi Y. 711 
2011. Structure of the measles virus hemagglutinin bound to its cellular receptor 712 
SLAM. Nat Struct Mol Biol 18:135-41. 713 
25. Noyce RS, Bondre DG, Ha MN, Lin LT, Sisson G, Tsao MS, Richardson CD. 2011. 714 
Tumor cell marker PVRL4 (nectin 4) is an epithelial cell receptor for measles virus. 715 
PLoS Pathog 7:e1002240. 716 
26. Tatsuo H, Ono N, Tanaka K, Yanagi Y. 2000. SLAM (CDw150) is a cellular receptor 717 
for measles virus. Nature 406:893-7. 718 
27. Plemper RK, Brindley MA, Iorio RM. 2011. Structural and mechanistic studies of 719 
measles virus illuminate paramyxovirus entry. PLoS Pathog 7:e1002058. 720 
28. Brindley MA, Takeda M, Plattet P, Plemper RK. 2012. Triggering the measles virus 721 
membrane fusion machinery. Proc Natl Acad Sci U S A 109:E3018-27. 722 
29. Bloyet LM, Brunel J, Dosnon M, Hamon V, Erales J, Gruet A, Lazert C, Bignon C, 723 
Roche P, Longhi S, Gerlier D. 2016. Modulation of Re-initiation of Measles Virus 724 
Transcription at Intergenic Regions by PXD to NTAIL Binding Strength. PLoS Pathog 725 
12:e1006058. 726 
30. Goncalves-Carneiro D, McKeating JA, Bailey D. 2017. The Measles Virus Receptor 727 
SLAMF1 Can Mediate Particle Endocytosis. J Virol 91. 728 
31. Heaton MP, Smith TPL, Freking BA, Workman AM, Bennett GL, Carnahan JK, 729 
Kalbfleisch TS. 2017. Using sheep genomes from diverse U.S. breeds to identify 730 
missense variants in genes affecting fecundity. F1000Res 6:1303. 731 
32. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, O'Donnell-732 
Luria AH, Ware JS, Hill AJ, Cummings BB, Tukiainen T, Birnbaum DP, Kosmicki JA, 733 
Duncan LE, Estrada K, Zhao F, Zou J, Pierce-Hoffman E, Berghout J, Cooper DN, 734 
Deflaux N, DePristo M, Do R, Flannick J, Fromer M, Gauthier L, Goldstein J, Gupta 735 
N, Howrigan D, Kiezun A, Kurki MI, Moonshine AL, Natarajan P, Orozco L, Peloso 736 
GM, Poplin R, Rivas MA, Ruano-Rubio V, Rose SA, Ruderfer DM, Shakir K, Stenson 737 
PD, Stevens C, Thomas BP, Tiao G, Tusie-Luna MT, Weisburd B, Won HH, Yu D, 738 
Altshuler DM, et al. 2016. Analysis of protein-coding genetic variation in 60,706 739 
humans. Nature 536:285-91. 740 
 o
n
 Septem
ber 24, 2018 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
23 
 
33. Griffin DE. 2016. The Immune Response in Measles: Virus Control, Clearance and 741 
Protective Immunity. Viruses 8. 742 
34. Holzer B, Hodgson S, Logan N, Willett B, Baron MD. 2016. Protection of Cattle 743 
against Rinderpest by Vaccination with Wild-Type but Not Attenuated Strains of 744 
Peste des Petits Ruminants Virus. J Virol 90:5152-62. 745 
35. Logan N, McMonagle E, Drew AA, Takahashi E, McDonald M, Baron MD, Gilbert M, 746 
Cleaveland S, Haydon DT, Hosie MJ, Willett BJ. 2016. Efficient generation of 747 
vesicular stomatitis virus (VSV)-pseudotypes bearing morbilliviral glycoproteins and 748 
their use in quantifying virus neutralising antibodies. Vaccine 34:814-22. 749 
36. Tahara M, Burckert JP, Kanou K, Maenaka K, Muller CP, Takeda M. 2016. Measles 750 
Virus Hemagglutinin Protein Epitopes: The Basis of Antigenic Stability. Viruses 8. 751 
37. Tahara M, Ohno S, Sakai K, Ito Y, Fukuhara H, Komase K, Brindley MA, Rota PA, 752 
Plemper RK, Maenaka K, Takeda M. 2013. The receptor-binding site of the measles 753 
virus hemagglutinin protein itself constitutes a conserved neutralizing epitope. J Virol 754 
87:3583-6. 755 
38. Nambulli S, Sharp CR, Acciardo AS, Drexler JF, Duprex WP. 2016. Mapping the 756 
evolutionary trajectories of morbilliviruses: what, where and whither. Curr Opin Virol 757 
16:95-105. 758 
39. Sun Z, Li A, Ye H, Shi Y, Hu Z, Zeng L. 2010. Natural infection with canine distemper 759 
virus in hand-feeding Rhesus monkeys in China. Vet Microbiol 141:374-8. 760 
40. Sakai K, Nagata N, Ami Y, Seki F, Suzaki Y, Iwata-Yoshikawa N, Suzuki T, Fukushi 761 
S, Mizutani T, Yoshikawa T, Otsuki N, Kurane I, Komase K, Yamaguchi R, 762 
Hasegawa H, Saijo M, Takeda M, Morikawa S. 2013. Lethal canine distemper virus 763 
outbreak in cynomolgus monkeys in Japan in 2008. J Virol 87:1105-14. 764 
41. Sakai K, Yoshikawa T, Seki F, Fukushi S, Tahara M, Nagata N, Ami Y, Mizutani T, 765 
Kurane I, Yamaguchi R, Hasegawa H, Saijo M, Komase K, Morikawa S, Takeda M. 766 
2013. Canine distemper virus associated with a lethal outbreak in monkeys can 767 
readily adapt to use human receptors. J Virol 87:7170-5. 768 
42. Nikolin VM, Olarte-Castillo XA, Osterrieder N, Hofer H, Dubovi E, Mazzoni CJ, 769 
Brunner E, Goller KV, Fyumagwa RD, Moehlman PD, Thierer D, East ML. 2017. 770 
Canine distemper virus in the Serengeti ecosystem: molecular adaptation to different 771 
carnivore species. Mol Ecol 26:2111-2130. 772 
43. Sawatsky B, Cattaneo R, von Messling V. 2018. Canine Distemper Virus Spread and 773 
Transmission to Naive Ferrets: Selective Pressure on SLAM-Dependent Entry. J 774 
Virol doi:10.1128/jvi.00669-18. 775 
44. Ohishi K, Ando A, Suzuki R, Takishita K, Kawato M, Katsumata E, Ohtsu D, Okutsu 776 
K, Tokutake K, Miyahara H, Nakamura H, Murayama T, Maruyama T. 2010. Host-777 
virus specificity of morbilliviruses predicted by structural modeling of the marine 778 
mammal SLAM, a receptor. Comp Immunol Microbiol Infect Dis 33:227-41. 779 
45. Morizono K, Chen IS. 2011. Receptors and tropisms of envelope viruses. Curr Opin 780 
Virol 1:13-8. 781 
46. Zeltina A, Bowden TA, Lee B. 2016. Emerging Paramyxoviruses: Receptor Tropism 782 
and Zoonotic Potential. PLoS Pathog 12:e1005390. 783 
47. Drexler JF, Corman VM, Muller MA, Maganga GD, Vallo P, Binger T, Gloza-Rausch 784 
F, Cottontail VM, Rasche A, Yordanov S, Seebens A, Knornschild M, Oppong S, Adu 785 
Sarkodie Y, Pongombo C, Lukashev AN, Schmidt-Chanasit J, Stocker A, Carneiro 786 
AJ, Erbar S, Maisner A, Fronhoffs F, Buettner R, Kalko EK, Kruppa T, Franke CR, 787 
Kallies R, Yandoko ER, Herrler G, Reusken C, Hassanin A, Kruger DH, Matthee S, 788 
Ulrich RG, Leroy EM, Drosten C. 2012. Bats host major mammalian 789 
paramyxoviruses. Nat Commun 3:796. 790 
 o
n
 Septem
ber 24, 2018 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
24 
 
48. Welstead GG, Iorio C, Draker R, Bayani J, Squire J, Vongpunsawad S, Cattaneo R, 791 
Richardson CD. 2005. Measles virus replication in lymphatic cells and organs of 792 
CD150 (SLAM) transgenic mice. Proc Natl Acad Sci U S A 102:16415-20. 793 
49. Chinnakannan SK, Nanda SK, Baron MD. 2013. Morbillivirus v proteins exhibit 794 
multiple mechanisms to block type 1 and type 2 interferon signalling pathways. PLoS 795 
One 8:e57063. 796 
50. Shu Y, McCauley J. 2017. GISAID: Global initiative on sharing all influenza data - 797 
from vision to reality. Euro Surveill 22. 798 
51. McBrien J, Murphy J, Gill D, Cronin M, O'Donovan C, Cafferkey MT. 2003. Measles 799 
outbreak in Dublin, 2000. Pediatr Infect Dis J 22:580-4. 800 
52. Ishikawa H, Meng F, Kondo N, Iwamoto A, Matsuda Z. 2012. Generation of a dual-801 
functional split-reporter protein for monitoring membrane fusion using self-802 
associating split GFP. Protein Eng Des Sel 25:813-20. 803 
53. Takada A, Robison C, Goto H, Sanchez A, Murti KG, Whitt MA, Kawaoka Y. 1997. A 804 
system for functional analysis of Ebola virus glycoprotein. Proceedings of the 805 
National Academy of Sciences of the United States of America 94:14764-9. 806 
54. Whitt MA. 2010. Generation of VSV pseudotypes using recombinant DeltaG-VSV for 807 
studies on virus entry, identification of entry inhibitors, and immune responses to 808 
vaccines. Journal of Virological Methods 169:365-74. 809 
55. Bailey D, Chard LS, Dash P, Barrett T, Banyard AC. 2007. Reverse genetics for 810 
peste-des-petits-ruminants virus (PPRV): promoter and protein specificities. Virus 811 
Res 126:250-5. 812 
56. Cathomen T, Naim HY, Cattaneo R. 1998. Measles viruses with altered envelope 813 
protein cytoplasmic tails gain cell fusion competence. J Virol 72:1224-34. 814 
57. Keeling MJ, Rohani P. 2011. Modeling infectious diseases in humans and animals. 815 
Princeton University Press. 816 
58. Crooks GE, Hon G, Chandonia JM, Brenner SE. 2004. WebLogo: a sequence logo 817 
generator. Genome Res 14:1188-90. 818 
59. Zhang Y. 2008. I-TASSER server for protein 3D structure prediction. BMC 819 
bioinformatics 9:40. 820 
60. Zahur A, Ullah A, Irshad H, Farooq M, Hussain M, Jahangir M. Epidemiological 821 
investigations of a peste des petits ruminants (PPR) outbreak in Afghan sheep in 822 
Pakistan. 823 
 824 
 o
n
 Septem
ber 24, 2018 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
 o
n
 Septem
ber 24, 2018 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
 o
n
 Septem
ber 24, 2018 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
 o
n
 Septem
ber 24, 2018 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
 o
n
 Septem
ber 24, 2018 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
 o
n
 Septem
ber 24, 2018 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
 o
n
 Septem
ber 24, 2018 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
 o
n
 Septem
ber 24, 2018 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
 o
n
 Septem
ber 24, 2018 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
 o
n
 Septem
ber 24, 2018 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
 o
n
 Septem
ber 24, 2018 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
